Which has better earnings & valuation, OPK or INVA?

Innoviva has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OPKO Health $606.90M 1.85 -$225.68M -$0.27 N/A Innoviva $411.33M 4.24 $271.17M $6.01 3.93

Is OPK or INVA more profitable?

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -36.63%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity. Company Net Margins Return on Equity Return on Assets OPKO Health -36.63% -16.78% -10.98% Innoviva 119.89% 33.33% 22.67%

Does the media prefer OPK or INVA?

In the previous week, Innoviva had 12 more articles in the media than OPKO Health. MarketBeat recorded 13 mentions for Innoviva and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.74 beat Innoviva's score of -0.52 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Which has preferable valuation and earnings, OPK or NVAX?

Novavax has higher revenue and earnings than OPKO Health. Novavax is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OPKO Health $606.90M 1.85 -$225.68M -$0.27 N/A Novavax $1.12B 1.30 $440.30M -$0.58 N/A

Is OPK or NVAX more profitable?

Novavax has a net margin of -14.73% compared to OPKO Health's net margin of -36.63%. Novavax's return on equity of -14.82% beat OPKO Health's return on equity. Company Net Margins Return on Equity Return on Assets OPKO Health -36.63% -16.78% -10.98% Novavax -14.73% -14.82% 1.23%

Does the media favor OPK or NVAX?

In the previous week, Novavax had 6 more articles in the media than OPKO Health. MarketBeat recorded 7 mentions for Novavax and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.74 beat Novavax's score of 0.41 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer OPK or ZBIO?

In the previous week, Zenas BioPharma had 2 more articles in the media than OPKO Health. MarketBeat recorded 3 mentions for Zenas BioPharma and 1 mentions for OPKO Health. Zenas BioPharma's average media sentiment score of 0.90 beat OPKO Health's score of 0.74 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OPKO Health (OPK) Competitors

$1.49 +0.03 (+2.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.01 (+0.34%)

As of 07:47 PM Eastern

Compare

OPK vs. CLDX, BCRX, INVA, NVAX, and ZBIO

Should you buy OPKO Health stock or one of its competitors? MarketBeat compares OPKO Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OPKO Health include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does OPKO Health compare to Celldex Therapeutics?

OPKO Health (NASDAQ:OPK) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

64.6% of OPKO Health shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

OPKO Health presently has a consensus price target of $1.55, indicating a potential upside of 4.03%. Celldex Therapeutics has a consensus price target of $49.30, indicating a potential upside of 45.94%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

OPKO Health has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.85	-$225.68M	-$0.27	N/A
Celldex Therapeutics	$1.54M	1,721.68	-$258.76M	-$4.26	N/A

Celldex Therapeutics has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Celldex Therapeutics	N/A	-50.72%	-46.59%

OPKO Health has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, OPKO Health had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 1 mentions for OPKO Health and 0 mentions for Celldex Therapeutics. OPKO Health's average media sentiment score of 0.74 beat Celldex Therapeutics' score of 0.00 indicating that OPKO Health is being referred to more favorably in the media.

Company	Overall Sentiment
OPKO Health	Positive
Celldex Therapeutics	Neutral

Summary

OPKO Health beats Celldex Therapeutics on 11 of the 16 factors compared between the two stocks.

How does OPKO Health compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

BioCryst Pharmaceuticals presently has a consensus target price of $20.70, indicating a potential upside of 107.54%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 4.03%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

OPKO Health has a net margin of -36.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. OPKO Health's return on equity of -16.78% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
OPKO Health	-36.63%	-16.78%	-10.98%

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 44.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 1 articles in the media. OPKO Health's average media sentiment score of 0.74 beat BioCryst Pharmaceuticals' score of 0.00 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCryst Pharmaceuticals	Neutral
OPKO Health	Positive

BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than OPKO Health. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.90	$263.86M	-$1.78	N/A
OPKO Health	$606.90M	1.85	-$225.68M	-$0.27	N/A

Summary

BioCryst Pharmaceuticals and OPKO Health tied by winning 8 of the 16 factors compared between the two stocks.

How does OPKO Health compare to Innoviva?

OPKO Health (NASDAQ:OPK) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Innoviva has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.85	-$225.68M	-$0.27	N/A
Innoviva	$411.33M	4.24	$271.17M	$6.01	3.93

OPKO Health has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

OPKO Health currently has a consensus price target of $1.55, indicating a potential upside of 4.03%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 53.13%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Innoviva had 12 more articles in the media than OPKO Health. MarketBeat recorded 13 mentions for Innoviva and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.74 beat Innoviva's score of -0.52 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 44.7% of OPKO Health shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -36.63%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Innoviva	119.89%	33.33%	22.67%

Summary

Innoviva beats OPKO Health on 12 of the 17 factors compared between the two stocks.

How does OPKO Health compare to Novavax?

OPKO Health (NASDAQ:OPK) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

OPKO Health has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market.

In the previous week, Novavax had 6 more articles in the media than OPKO Health. MarketBeat recorded 7 mentions for Novavax and 1 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.74 beat Novavax's score of 0.41 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

OPKO Health currently has a consensus target price of $1.55, indicating a potential upside of 4.03%. Novavax has a consensus target price of $13.00, indicating a potential upside of 46.15%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Novavax is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

Novavax has higher revenue and earnings than OPKO Health. Novavax is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.85	-$225.68M	-$0.27	N/A
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A

Novavax has a net margin of -14.73% compared to OPKO Health's net margin of -36.63%. Novavax's return on equity of -14.82% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Novavax	-14.73%	-14.82%	1.23%

Summary

Novavax beats OPKO Health on 10 of the 17 factors compared between the two stocks.

How does OPKO Health compare to Zenas BioPharma?

OPKO Health (NASDAQ:OPK) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

OPKO Health currently has a consensus price target of $1.55, indicating a potential upside of 4.03%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 103.15%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

OPKO Health has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market.

In the previous week, Zenas BioPharma had 2 more articles in the media than OPKO Health. MarketBeat recorded 3 mentions for Zenas BioPharma and 1 mentions for OPKO Health. Zenas BioPharma's average media sentiment score of 0.90 beat OPKO Health's score of 0.74 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health has higher revenue and earnings than Zenas BioPharma. OPKO Health is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.85	-$225.68M	-$0.27	N/A
Zenas BioPharma	$10M	137.62	-$377.74M	-$8.47	N/A

64.6% of OPKO Health shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zenas BioPharma has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Zenas BioPharma	N/A	-99.99%	-58.06%

Summary

OPKO Health beats Zenas BioPharma on 9 of the 17 factors compared between the two stocks.

Get OPKO Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPK vs. The Competition

Export

Metric	OPKO Health	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.10B	$7.09B	$6.54B	$12.32B
Dividend Yield	N/A	1.27%	2.68%	5.88%
P/E Ratio	-5.52	49.00	25.39	23.96
Price / Sales	1.85	75.55	530.17	107.90
Price / Cash	N/A	25.22	45.29	53.76
Price / Book	0.89	7.31	10.76	6.41
Net Income	-$225.68M	$159.20M	$3.56B	$337.14M
7 Day Performance	5.67%	0.09%	1.37%	-0.48%
1 Month Performance	17.32%	-0.54%	0.81%	0.49%
1 Year Performance	15.50%	5.77%	30.53%	28.16%

OPKO Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPK OPKO Health	1.1881 of 5 stars	$1.49 +2.1%	$1.55 +4.0%	+15.0%	$1.10B	$606.90M	N/A	1,373
CLDX Celldex Therapeutics	1.6372 of 5 stars	$32.12 +2.7%	$49.30 +53.5%	+61.7%	$2.45B	$1.54M	N/A	150	Gap Up
BCRX BioCryst Pharmaceuticals	2.1941 of 5 stars	$9.06 +4.1%	$20.70 +128.5%	-6.1%	$2.21B	$874.84M	N/A	530	Options Volume
INVA Innoviva	3.7639 of 5 stars	$22.42 -1.4%	$36.20 +61.5%	+13.2%	$1.68B	$411.33M	3.73	100	Trending News Analyst Forecast Analyst Revision
NVAX Novavax	1.8499 of 5 stars	$9.21 +3.7%	$12.13 +31.7%	+42.6%	$1.46B	$1.12B	N/A	1,990	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPK) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does OPKO Health compare to Celldex Therapeutics?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Summary

How does OPKO Health compare to Innoviva?

Summary

How does OPKO Health compare to Novavax?

Summary

How does OPKO Health compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does OPKO Health compare to Celldex Therapeutics?

Do insiders and institutionals believe in OPK or CLDX?

Do analysts recommend OPK or CLDX?

Which has preferable earnings & valuation, OPK or CLDX?

Is OPK or CLDX more profitable?

Which has more volatility and risk, OPK or CLDX?

Does the media favor OPK or CLDX?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Do analysts recommend BCRX or OPK?

Is BCRX or OPK more profitable?

Do insiders & institutionals hold more shares of BCRX or OPK?

Does the media prefer BCRX or OPK?

Which has more risk & volatility, BCRX or OPK?

Which has stronger earnings and valuation, BCRX or OPK?

Summary

How does OPKO Health compare to Innoviva?

Which has better earnings & valuation, OPK or INVA?

Which has more volatility & risk, OPK or INVA?

Do analysts recommend OPK or INVA?

Does the media prefer OPK or INVA?

Do institutionals and insiders hold more shares of OPK or INVA?

Is OPK or INVA more profitable?

Summary

How does OPKO Health compare to Novavax?

Do insiders and institutionals believe in OPK or NVAX?

Which has more risk & volatility, OPK or NVAX?

Does the media favor OPK or NVAX?

Do analysts rate OPK or NVAX?

Which has preferable valuation and earnings, OPK or NVAX?

Is OPK or NVAX more profitable?

Summary

How does OPKO Health compare to Zenas BioPharma?

Do analysts rate OPK or ZBIO?

Which has more risk & volatility, OPK or ZBIO?

Does the media prefer OPK or ZBIO?

Which has stronger valuation and earnings, OPK or ZBIO?

Do institutionals & insiders believe in OPK or ZBIO?

Is OPK or ZBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools